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Significance of S-phase fraction and hormone receptor content in the
management of young breast cancer patients
0. Stal, J. Carstensen, T. Hatschek & B. Nordenskjold
South-East Sweden Breast Cancer Group*, Department ofOncology, University Hospital, S-581 85 Linkoping, Sweden.
Summary Tumours from 336 breast cancer patients under the age of 50 were analysed for hormone receptor
content and by DNA flow cytometry. Sixty-six percent of the tumours were positive for estrogen receptors
(ER), 60% were progesterone receptor (PR) positive and 42% showed DNA diploid profiles. DNA hypodip-
loid tumours were relatively frequent (7%), especially in patients aged 40 years or less (11%). S-phase fraction
(SPF), with a mean of 10%, correlated significantly with receptor status, DNA ploidy, lymph node status,
tumour size and age. With a median follow-up period of 34 months, the distant recurrence-free interval was
independently predicted by lymph node status, tumour size, SPF and PR content. Amongst the 212 patients
who had not received adjuvant systemic treatment, receptor status was, in addition to lymph node status and
SPF, independently related to distant recurrence rate. A high SPF identified a subgroup with high recurrence
rate, comprising approximately one third of the node-negative patients. Similarly, the one third of node-
positive patients who had PR-positive tumours with a low S-phase fraction formed a subgroup with low
recurrence rate. We conclude that hormone receptor assays and DNA flow cytometry should be useful tools in
the management of breast cancer patients less than 50 years of age.
From the analysis of a large number of clinical trials it has
been concluded that patients with early breast cancer benefit
from adjuvant chemotherapy or endocrine therapy in addi-
tion to localised treatment (Early Breast Cancer Trialists
Collaborative Group, 1988). While administration of tamox-
ifen seems to be most efficient amongst postmenopausal
women, chemotherapy prolongs the survival primarily in
young patients. As a whole, approximately one third of the
early deaths in premenopausal patients can be avoided or
delayed by combination chemotherapy.
Selective use of systemic therapy to maximise the benefit to
individual patients becomes possible if subgroups at different
risk can be identified. This is especially relevant amongst
node-negative patients showing a 5-year breast cancer sur-
vival rate of 90% (Carter et al., 1989). A growing number of
reports indicate that hormone receptor status and pro-
liferative indices could be used to predict the rate of recur-
rence and survival (Clark et al., 1989; Crowe et al., 1982;
Godolphin et al., 1981; Hatschek et al., 1989; Sigurdsson et
al., 1990; Skoog et al., 1987; Spyratos et al., 1989; Stal et al.,
1989; Thorpe et al., 1987; Toikkanen et al., 1989). While
S-phase fraction has been related to the recurrence-free sur-
vival of systemically untreated patients with breast cancer
(Hery et al., 1987; Silvestrini et al., 1989), conflicting results
have been presented on the prognostic value of hormone
receptors in the same group of patients. A favourable prog-
nosis for premenopausal patients with receptor positive
tumours was found by Thorpe et al. (1987), while no survival
difference due to receptor status was observed amongst post-
menopausal patients. In contrast, the prognostic value of ER
status was confined to postmenopausal patients in a similar
study (Crowe et al., 1982).
As age seems to be an important factor for the choice of
various adjuvant treatments it should be relevant to study
different age groups separately. In the present series of 336
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patients under the age of 50, DNA flow cytometric variables
and hormone receptor data have been analysed together with
other prognostic factors in order to find subgroups of
patients at low and high risk of recurrence, respectively.
Material and methods
Patients
The present investigation includes women under the age of
50 diagnosed for primary breast cancer either in the South-
East Sweden Health Care Region or at the hospitals in
Eskilstuna, Karlstad and Orebro. Frozen specimens were
delivered to the reference laboratory for steroid receptor
assays in Linkoping. In addition, DNA flow cytometry was
performed consecutively from 1985. The present series com-
prises 336 cases diagnosed from the beginning of 1985 to the
end of 1989. The patients had unilateral breast cancer, with-
out previous history of cancer and without evidence of dis-
tant dissemination at diagnosis. For all the patients, S-phase
fraction had been evaluated, representing 79% of the
tumours analysed by DNA flow cytometry. For women aged
40-74 years, mammography screening programs were intro-
duced between the end of 1986 and October 1987 in four of
the six counties involved. In the county of bstergbtland a
mammography screening trial had been started in 1978
before the general screening program was introduced in 1987.
Patients in stage I and II, according to the UICC, were
operated on with either modified radical mastectomy or sec-
tor resection. In all cases axillary lymph node dissection was
performed. Those treated with breast-conserving surgery
received postoperative radiotherapy, 54 Gy in 27 fractions to
the breast parenchyma. Mastectomised patients who were
found to have node metastasis underwent radiotherapy,
45 Gy in 20 fractions, including the scar and regional nodes.
None received preoperative therapy. One third of the patients
received adjuvant treatment; either CMF (10%), tamoxifen
(22%) or a combination of both (1%). Information about
adjuvant treatment was not available in 18 cases. Lymph
node status and tumour size were decided by histo-
pathological examination.
Follow-up
Follow-up visits took place at least twice yearly the first 5
years and thereafter yearly. Chest X-rays, bone scans, mam-
mography and blood tests were performed if clinical signs or
symptoms indicated possible relapse. The follow-up period
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ranged between 1 and 6 years with a median follow-up of 34
months. Loco-regional recurrence was recorded in 14
patients, distant metastasis in 65 patients of whom 40 died
from breast cancer.
Hormone receptor analysis
The specimens were collected from fresh surgical resections
and stored below - 70°C before the analysis. Tumours diag-
nosed during the first half of the period were analysed for
estrogen (ER) and progesterone (PR) receptors as described
by Wrange et al. (1978). Cytosol was incubated with 5 nM
3H-estradiol (ER) or 100 nM R5020 (PR), respectively, and
the receptors were isolated by isoelectric focusing in poly-
acrylamide gel. From the beginning of 1988 we used the
Abbott EIA assay. Tumour tissue was homogenised at 0°C in
phosphate buffer using a micro-dismembrator and the
homogenate was centrifuged at 20,000g for 20 min. The
DNA content of the pellet was measured by the Burton
method and the receptors were analysed from the superna-
tant according to the instructions given by the manufacturer
(Abbott laboratories, USA). Briefly, specific monoclonal
antibodies bound to polysterene beads were added and were
then separated from the supernatant. After addition of a
second antibody, the intensity of colour developed was
registered with a spectrophotometer, and the amount of
receptor was obtained using a standard curve. Similar to the
ligand technique, the receptor concentrations were expressed
as fmol receptor per tLg DNA. A cut-off value of
0.1 fmoljg-' DNA was used for receptor positivity. The
correlation between the methods was high in a comparative
study in our laboratory (unpublished data) as also found in
other studies (Ferno et al., 1986; Thorpe, 1987). The absolute
levels, however, are significantly higher with EIA. Therefore,
concentration values obtained with the ligand technique in
the present study were multiplied by a constant, which was
equal to the ratio between the EIA mean and the ligand
mean. This resulted in comparable distributions of receptor
content for the two subgroups of tumours. The potential
influence of type of assay technique on survival analysis was
investigated by introducing interaction terms based on recep-
tor content and assay type in the Cox analysis. These inter-
action terms showed no significant values.
DNAflow cytometry
A small piece of the tumour specimen was minced in citrate
buffer and afterwards a mixture of chicken and trout red
blood cells was added as internal marker cells. A suspension
of isolated nuclei was prepared without washing steps as
described by Vindelov et al. (1983). The procedure included
treatment with a detergent (0.1% NP40), trypsin and RNAse
followed by filtering through a 41 ytm nylon mesh. The
suspension was stained with propidium iodide and measured
within 1 h. In addition, an imprint from the tissue was
stained and examined to ascertain the presence of tumour
cells in the sample.
Cell suspensions were analysed with a Leitz MPV FLOW
flow cytometer (Leitz GmbH, Wetzlar, FRG) interfaced to a
Monroe OC8888 personal computer system (Litton Business,
USA). The software used for data acquisition and analysis
was developed in our laboratory. Illumination from a high-
pressure mercury lamp was used with light filtered through
an AL interference filter with peak transmission at 546 nm
and with a 20nm bandwidth. Emitted fluorescence was
recorded after passing a dicroic mirror TK 580 and a 590 nm
long-pass filter.
Histogram evaluation
Usually, 20,000 cells were measured. DNA indices (DI) were
calculated after zero point adjustment by using the chicken
and trout red blood cells as internal controls. These showed
35% and 80% respectively of the fluorescence of human
(female) diploid cells stained with propidium iodide. The
coefficient of variation (CV) of tumour Go/, peaks was
estimated from the width of the peak at half-maximum peak
height. Median CV was 3.6%. Tumours were classified into
six categories of DNA ploidy considering both the number of
GO/, peaks and the DNA index. A single peak in the near-
diploid range was classified as DNA diploid. If an additional
peak was present the tumour was classified into one of the
five non-diploid categories depending on DI. Thus, tumours
were considered DNA hypodiploid for DI< 1.00, hyperdip-
loid for DI in the range 1.01-1.90, tetraploid for DI ranged
1.91-2.10 and hypertetraploid for a DI greater than 2.10. If
more than one non-diploid peak was observed the tumour
was classifed as multiploid. Small aneuploid or tetraploid
populations, with a minimum of 1,000 cells, were separated
from artefacts or diploid G2/M cells by looking for a corres-
ponding G2/M peak. In the survival analysis, DNA diploid
and tetraploid tumours formed together a euploid category
and DNA hypodiploid, multiploid and hypertetraploid cases
were combined into one subgroup called 'other aneuploid'.
For the estimation of SPF a planimetric method was used,
assuming the S compartment to be rectangular distributed
(Baisch et al., 1975). The number of cells in S phase was
estimated by the software by multiplying the number of
channels between the GO/, and G2/M peaks by the mean
number of registrations per channel in an interval selected by
the user. The S-phase interval was chosen in such a way that
the influence of debris or disturbing peaks should be as small
as possible. Furthermore, additional peaks interfering with
the population of interest could be labelled by the user and
was then subtracted from the histogram by the software
before the calculation ofcell cycle parameters was performed.
The majority of the histograms were clean from background
debris to the right of the G2/M peak and peaks generated by
cell clumps were generally small. Therefore, background cor-
rection was not performed. The assessability of SPF was
highest for DNA diploid tumours (98%) and lowest for
multiploid cases (39%) while it was 79% for all tumours. The
mean S-phase value was 10.2% and the median was 8.9%.
Statistical methods
Relative recurrence and death rates were studied using the
proportional hazards method described by Cox (1972). The
product-limit method as described by Kaplan and Meier
(1958) was used for estimations of cumulative probability of
survival. Differences in SPF mean values between various
categories were tested using Student's t test or linear regres-
sion analysis. Relationships between grouped variables were
tested by means of chi-square tests for contingency tables
with ordered categories (Armitage & Berry, 1987). All P-
values cited were two-sided, and P-values less than 5% were
judged as statistically significant.
Results
Table I shows an overview of clinical and laboratory data
and presents the relationships between the variables. Fifty-
eight percent were node-negative and 57% of the tumours
had a size of 20 mm or less. In the node-positive subgroup
the proportion of small tumours was 44%. Two thirds of the
tumours were estrogen receptor positive and 58% showed an
abnormal DNA content. The frequencies of DNA hypodip-
loid, hyperdiploid, tetraploid, hypertetraploid and multiploid
tumours were 7%, 40%, 5%, 3% and 4% respectively. The
correlation between ER and PR status was high. Ten percent
were of type ER + PR- and 4% were ER-/PR +. ER-
positive tumours were more often DNA euploid and showed
a lower mean SPF compared to receptor negative cases.
Mean S-phase fraction increased significantly with the in-
creasing number of positive nodes as did the proportion of
DNA aneuploid tumours. Tumours larger than 20 mm were
significantly more often receptor negative, DNA aneuploid
and had a higher proliferation rate than smaller tumours.
Tumours with a high SPF as well as DNA aneuploid and708 0. STAL et al.
receptor negative tumours were more often found in younger
than in older patients. In particular, the proportion of DNA
hypodiploid tumours was higher in patients aged 40 years or
younger compared to the older group, with 11% and 5%,
respectively (p = 0.07).
Correlations to distant recurrence-free survival
During the observation period, 65 patients relapsed with
distant metastasis and 40 patients died from breast cancer.
Several variables were related to distant recurrence-free sur-
vival (Table II). Lymph node status, tumour size, S-phase
fraction and PR content were independent prognostic factors.
In addition, univariate analysis showed that decreasing age,
DNA aneuploidy and a low ER content were associated with
a high risk of recurrence. Estrogen receptor content became
an independent variable if PR status was excluded from the
multivariate analysis (P = 0.010). Patients with tumours hav-
ing a low or intermediate SPF had approximately the same
risk of recurrence while a S-phase fraction of 10% or greater
was associated with a much higher risk. SPF was related to
recurrence-free survival in different subgroups of lymph node
status. Amongst node-negative patients, two of 118 with a
low SPF (<10%) relapsed, while 22 of 78 patients with a
high SPF developed metastasis. DNA aneuploid tumours
were more aggressive than euploid tumours, especially the
subgroup comprising DNA hypodiploid, hypertetraploid and
multiploid tumours. This was most evident in the node-
negative subgroup (P<0.001). The difference was less pro-
nounced amongst node-positive patients and did not reach
statistical significance.
Systemically untreatedpatients
The distant recurrence-free survival amongst the 212 patients
who had not received adjuvant systemic treatment was
analysed separately (Table III). Nodal status, S-phase frac-
tion and PR status were identified as independent prognostic
factors. Tumours larger than 20 mm were associated with a
worse prognosis than smaller tumours, but the multivariate
TableI Interrelationships betweenreceptor status, DNAploidy, S-phase fraction, lymph node
status, tumour size and age
Receptor status DNA ploidy S-phasefraction
No. %ER+ %PR+ % Aneuploida Mean (%)
Lymph node status
0 196 65 61 49a 9.7a
1-3 94 74 64 54 10.5
>3 46 52 52 70 11.8
Tumour size
<20 mm 192 72b 66a 44c 9.OC
>20 mm 144 58 53 65 11.7
Age
<40 years 83 58 52 69b 12.9c
41 -49 years 253 69 63 48 9.3
ER status
ER-positive 222 85c 44c 8.3c
ER-negative 114 12 71 13.8
PR status
PR-positive 203 93c 46b 8.4c
PR-negative 133 25 64 12.9
DNA ploidy
Euploid 157 79c 69b 6.8c
Aneuploid 179 55 53 13.1
*Not including DNA tetraploid tumours. ap<o*o5, bp<0.01, cp<0.001.
Table II Distance recurrence-free survival analysed by the Cox model for all 336 patients
Univariate Multivariate
No. of No. of Testfor Adjusted Testfor
patients recurrences Rate ratio trend rate ratio trend
Lymph node status
0 196 24 1.0 1.0
1-3 94 19 1.6 P<0.001 1.3 P<0.001
> 3 46 22 5.2 4.4
Tumour size
< 20 mm 192 20 1.0 1.0
>20 mm 144 45 3.2 P<0.001 2.2 P = 0.0060
DNA ploidy
Euploid 157 17 1.0
Hyperdiploid 134 33 2.5 P<0.001
Other aneuploid 45 15 3.9
S-phase fraction
<5% 79 4 1.0 1.0
5-10% 102 7 1.2 P<0.001 1.1 P<0.001
> 10% 155 54 7.3 5.6
ER (fmoljig' DNA)
<0.1 114 38 1.00
0.1 222 27 0.33 P<0.001
PR (fmol jg- 'DNA)
<0.1 133 43 1.00 1.00
0.1 203 22 0.34 P<0.001 0.44 P= 0.0023
Age
<40 years 83 24 1.00
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analysis showed no significant difference in recurrence rate,
with a rate ratio of 1.2 (0.6-2.7, 95% confidence interval).
Progesterone receptor status could be replaced by ER status
as an independent prognostic variable (P = 0.013).
For the systemically untreated patients with node-negative
breast cancer, S-phase fraction and PR status were used in
combination in order to find groups at low and high risk of
recurrence. Approximately two thirds of the patients had
tumours with S-phase levels below 10% and showed a low
rate of recurrence (Figure 1). Amongst those with a high
S-phase fraction, tumours positive for PR seemed to be less
aggressive than PR-negative tumours. Tumour size, however,
did not contribute prognostic information in addition to S
phase fraction.
Amongst node-positive patients who did not receive
systemic therapy, cases which were both PR-positive and of
low S-phase rate formed a group at low risk comprising one
third of the patients (Figure 2). The cumulative recurrence-
free survival at 4 years was 90%. As observed in the node-
negative subgroup, the risk of relapse for patients with a high
SPF was dependent on PR status.
Local recurrence and breast cancer mortality
For breast cancer mortality, among the whole patient
population, the same independent variables were identified by
Cox analysis as were obtained for distant metastasis (Table
II). In the node-negative group, none of the 118 patients with
a S-phase value below 10% died during the observation
period, while the cumulative survival at 4 years was 70% for
those having a SPF of 10% or greater. Fourteen patients
developed a local recurrence. Those with large tumour size
(P = 0.04) and those with receptor negative tumours (ER,
P = 0.027; PR, P = 0.016) more often had a local recurrence.
Neither lymph node status nor S-phase fraction were
significantly related to local recurrence.
Node-negative without systemic treatment
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Figure 1 The distant recurrence-free survival related to SPF and
PR status in systemically untreated patients with node-negative
breast cancer.
Node-positive without systemic treatment
1.0 ' .
0 SPF < 10%, PR+ (n = 15)
0.8- i -
0.6- f
SPF < 10%, PR- (n = 5)
, SPF - 10%, PR+ (n = 12)
0.2 ---------- SPF-10%, PR- (n = 11)
0.0
60 0 12 24 36 48 60
Months
Figure 2 The distant recurrence-free survival related to SPF and
PR status in systemically untreated patients with node-positive
breast cancer.
Discussion
S-phase fraction and hormone receptor status contributed
prognostic information in addition to lymph node status and
tumour size in the present study of young patients. The same
has been found in several studies including breast cancer
patients of mixed ages (Hatschek et al., 1989; Kallioniemi et
al., 1988; Meyer & Province, 1988; Sigurdsson et al., 1990;
Stal et al., 1989). This similarity is in line with the fact that
age seems not to be an independent prognostic factor in
breast cancer (Clark et al., 1989; Kallioniemi et al., 1988;
Sigurdsson et al., 1990; Stal et al., 1991), although young
patients treated by surgery alone tend to relapse at a higher
rate than older ones (Simpson et al., 1988). This probably
reflects the fact that young patients more often have tumours
which are receptor negative, DNA aneuploid or of high
S-phase fraction than have older patients (Olsson et al., 1991;
Sigurdsson et al., 1990; Simpson et al., 1988; von Rosen et
al., 1986; Wilking et al., 1989). The present series indicates
that SPF is the one most strongly related to age. In a
recently published study of premenopausal women with
breast cancer, a high SPF in the tumour was related to early
use of oral contraceptives (Olsson et al., 1991).
While the clinical significance of ER and PR status is well
established in subgroups of patients receiving adjuvant hor-
monal treatment, the prognostic value in node-negative
patients treated by surgery alone, or in combination with
radiotherapy, is more controversial. For the latter subgroup,
premenopausal patients with receptor negative tumours
relapsed at a higher rate than those with receptor positive
tumours in two studies (Moot et al., 1987; Thorpe et al.,
1987), while there was no survival difference due to receptor
status amongst postmenopausal women in one of the studies
(Thorpe et al., 1987). On the other hand, a better prognosis
for patients with ER-positive tumours in the postmenopausal
group, but not in the premenopausal one was reported by
Crowe and colleagues (1982). Amongst the 169 systemically
untreated node-negative patients in the present study, PR
status was related to recurrence-free survival in the subgroup
with a high SPF (Figure 1). Furthermore, if all systemically
untreated patients were considered, PR status contributed
prognostic information in addition to that of nodal status
and SPF (Table III). To our knowledge, this relationship has
not been observed before.
Does a low SPF alone identify node-negative patients at
low risk? In other studies of early breast cancer, tumour size
has been taken into account in addition to SPF (O'Reilly et
al., 1990a; Sigurdsson et al., 1990). In the present study of
young patients, however, tumour size showed no additional
value, which may be due to its correlation with SPF (Table
I). The relatively high correlation between tumour size and
SPF may in turn be the result of repeatedly mammography
screening. Our data suggest that the subgroup of patients
with a high SPF could be candidates for adjuvant therapy.
For receptor positive cases, tamoxifen treatment has shown
to be effective in premenopausal as well as postmenopausal
patients (Fisher et al., 1989).
Amongst node-positive patients, PR-positive tumours with
low SPF formed a subgroup at low risk, comprising one
third of the patients (Figure 2). In contrast to our study,
untreated node-positive patients with low levels of SPF
showed fairly poor prognosis in the study of O'Reilly et al.
(1990b) with a 3-year recurrence-free survival rate of approx-
imately 50%. A possible explanation for this difference may
be, that while small tumours were rare in the English study,
almost half of the node-positive cases in the present series
were sized 20 mm or less. Possibly, the relatively large pro-
portion of patients identified at low risk in the present study
was influenced by population screening. Of the 15 untreated
patients identified at low risk, only two showed involvement
in more than three lymph nodes. Thus, the low-risk group
may not be representative for those having more than three
positive nodes, who were associated with a very poor prog-
nosis (Table III).
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Table III Multivariate analysis ofthe distant recurrence-free survival amongst
systemically untreated patients (Cox model)
No. of No. of Adjusted
patients recurrences rate ratio Testfor trend
Lymph node status
0 169 15 1.0
1-3 29 7 2.7 P<0.001
> 3 14 9 14.5
S-phase fraction
<5% 53 1 1.0
5-10% 75 4 1.9 P<0.001
" 10% 84 26 10.3
PR (fmolpg' DNA)
<0.1 79 22 1.00
0.1 133 9 0.31 P= 0.0046
of PR content in the present study, which is in agreement
with the high correlation observed between the two variables.
For postmenopausal patients the correlation has been shown
to be less close due to a relatively higher proportion of
ER + PR - tumours in this subgroup (Thorpe, 1987; Wilk-
ing et al., 1989).
As in the present study, DNA ploidy has shown prognostic
significance in node-negative breast cancer in contrast to
node-positive in some studies (Ewers et al., 1989; Toikkanen
et al., 1989). In the series of node-positive breast cancer
reported by Baildam et al. (1987), Hedley et al. (1987) and
Lykkesfeldt et al. (1988), DNA ploidy predicted recurrence
or mortality, but not independent of other prognostic factors.
No difference in recurrence-free survival due to DNA ploidy
was observed amongst premenopausal node-positive patients
in the study of Cornelisse et al. (1987). In contrast, SPF
appears to be an independent prognostic factor in both
subgroups of lymph node status, even after long follow-up
periods (Toikkanen et al., 1989). However, as SPF in most
studies is not assessed in approximately 20% of the samples,
DNA ploidy should be useful in such cases, especially as
regards node-negative breast cancer. In the present series, the
subgroup with DNA hypodiploid, hypertetraploid or multi-
ploid tumours exhibited the highest recurrence rate. In
patients aged 40 years or less, 11% of the tumours were
DNA hypodiploid, compared with 5% amongst those
between 41 and 49 years of age. This frequency continues to
decrease with increasing age (StAl et al., 1992). Further inves-
tigations are needed to explain this relationship.
While a high SPF strongly correlated with distant recur-
rence in the present study, it did not significantly predict
local recurrence. Similar results have been obtained by others
(Hery et al., 1987; Hatschek et al., 1989). Probably, fre-
quency of local recurrence is most influenced by the type of
local treatment, such as radiotherapy.
In conclusion, flow-cytometric S-phase fraction and hor-
mone receptor status have clinical significance in breast
cancer patients aged less than 50 years. A high SPF identified
a subgroup with high recurrence rate, comprising approx-
imately one third of the node-negative patients. Similarly, the
one third of node-positive patients who had PR-positive
tumours with a low S-phase fraction formed a subgroup with
a low recurrence rate.
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